600276 恒瑞医药
已收盘 12-25 15:00:00
资讯
新帖
简况
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
时代周报 · 14:21
光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事
恒瑞医药：SHR-A2102临床试验获批 聚焦实体瘤与食管癌
财中社 · 12-24 17:37
恒瑞医药：SHR-A2102临床试验获批 聚焦实体瘤与食管癌
恒瑞医药(600276.SH)：注射用SHR-A1904纳入突破性治疗品种名单
智通财经 · 12-24 16:54
恒瑞医药(600276.SH)：注射用SHR-A1904纳入突破性治疗品种名单
恒瑞医药祝您暖意相随，喜乐常安！
恒瑞医药官微 · 12-21
恒瑞医药祝您暖意相随，喜乐常安！
恒瑞医药：SHR-9539注射液获临床试验批准
南方财经网 · 12-19
恒瑞医药：SHR-9539注射液获临床试验批准
小摩增持恒瑞医药(01276)387.9413万股 每股作价72.5974港元
智通财经网 · 12-15
小摩增持恒瑞医药(01276)387.9413万股 每股作价72.5974港元
摩根大通在江苏恒瑞医药H股的多头头寸于12月9日从6.79%增至8.29%
美股速递 · 12-15
摩根大通在江苏恒瑞医药H股的多头头寸于12月9日从6.79%增至8.29%
恒瑞医药卵巢癌治疗药物氟唑帕利FZOCUS-1研究，载入全球肿瘤学顶刊《CA》
新浪科技 · 12-15
恒瑞医药卵巢癌治疗药物氟唑帕利FZOCUS-1研究，载入全球肿瘤学顶刊《CA》
国信证券：FXI抑制剂有望成为下一代抗凝药物 建议关注恒瑞医药(600276.SH)
智通财经 · 12-15
国信证券：FXI抑制剂有望成为下一代抗凝药物 建议关注恒瑞医药(600276.SH)
12月12日恒瑞医药现1笔大宗交易 机构净卖出358.16万元
证券之星 · 12-12
12月12日恒瑞医药现1笔大宗交易 机构净卖出358.16万元
恒瑞医药：SHR-A1811(sc)注射液获临床试验批准
南方财经网 · 12-12
恒瑞医药：SHR-A1811(sc)注射液获临床试验批准
恒瑞医药（600276）披露召开2025年第二次临时股东会通知，12月11日股价上涨0.03%
证券之星 · 12-11
恒瑞医药（600276）披露召开2025年第二次临时股东会通知，12月11日股价上涨0.03%
恒瑞医药(01276)药品纳入国家医保目录
智通财经 · 12-07
恒瑞医药(01276)药品纳入国家医保目录
恒瑞医药最新公告：9款药品首次纳入国家医保目录11款药品新增或续约成功
证券之星 · 12-07
恒瑞医药最新公告：9款药品首次纳入国家医保目录11款药品新增或续约成功
最新富时罗素中国调仓全解读
港股解码 · 12-04
最新富时罗素中国调仓全解读
富时中国50指数调整：纳入中国宏桥(01378)、宁德时代(03750)、恒瑞医药(01276)，剔除中信建投证券(06066)等
智通财经 · 12-03
富时中国50指数调整：纳入中国宏桥(01378)、宁德时代(03750)、恒瑞医药(01276)，剔除中信建投证券(06066)等
恒瑞医药最新公告：董事会提名聘任朱国新为公司高级副总裁
证券之星 · 12-03
恒瑞医药最新公告：董事会提名聘任朱国新为公司高级副总裁
恒瑞医药回购890万股 金额5.95亿元
财中社 · 12-02
恒瑞医药回购890万股 金额5.95亿元
GIC Private Limited增持恒瑞医药(01276)42.24万股 每股作价约74.96港元
智通财经 · 12-01
GIC Private Limited增持恒瑞医药(01276)42.24万股 每股作价约74.96港元
恒瑞医药获大摩增持约177.06万股 每股均价69.65港元
新浪港股 · 11-28
恒瑞医药获大摩增持约177.06万股 每股均价69.65港元
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇胺片、碘佛醇注射液。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":61.4,"timestamp":1766646000000,"preClose":61.23,"halted":0,"volume":15518175,"delay":0,"changeRate":0.0028,"floatShares":6379000000,"shares":6637000000,"eps":1.1252,"marketStatus":"已收盘","change":0.17,"latestTime":"12-25 15:00:00","open":61.22,"high":61.66,"low":61.03,"amount":952000000,"amplitude":0.0103,"askPrice":61.41,"askSize":196,"bidPrice":61.4,"bidSize":769,"shortable":0,"etf":0,"ttmEps":1.1252,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766712600000},"marketStatusCode":5,"adr":0,"adjPreClose":61.23,"symbolType":"stock","openAndCloseTimeList":[[1766626200000,1766633400000],[1766638800000,1766646000000]],"highLimit":67.35,"lowLimit":55.11,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":6.85,"roa":"--","peRate":54.568077,"roe":"11.09%","epsLYR":1,"committee":0.608955,"marketValue":407524000000,"turnoverRate":0.0024,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-29。","hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":71.2,"timestamp":1766549304005,"preClose":71.35,"halted":0,"volume":656224,"delay":0,"premium":"+4.51"},"floatMarketCap":391671000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064130708.USD","LU1997244956.HKD","LU1146622755.USD","03692","LU1064131003.USD","09995","LU1997245177.USD","BK1589","BK0188","02509","LU0405327494.USD","BK0012","LU0405327148.USD","LU1781817850.SGD","BK0057","LU2097828474.EUR","01167","603087","BK0060","BK1593","BK1161","LU2495084118.USD","LU2488822045.USD","LU2097828557.USD","BK1574","000661","688428","688062","LU0502904849.HKD","BK0183","688336","BK0239","LU2097828631.EUR","02096","LU2148510915.USD","600276","002755","LU2097828714.EUR","LU1969619763.USD","02142","BK0028","BK0196","LU2580892862.HKD","01530","LU1328615791.USD","06978","688331","01801","LU2097828805.USD","LU1997245094.SGD"],"gpt_icon":0},{"id":"2593475884","title":"恒瑞医药：SHR-A2102临床试验获批 聚焦实体瘤与食管癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2593475884","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593475884?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:37","pubTimestamp":1766569070,"startTime":"0","endTime":"0","summary":"12月24日，恒瑞医药（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司近日获得国家药品监督管理局核准签发的关于注射用SHR-A2102的《药物临床试验批准通知书》，将于近期开展临床试验。该药物为公司自主研发的靶向Nectin-4的抗体药物偶联物，具有知识产权，其有效载荷是拓扑异构酶Ⅰ抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600814636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2580892862.HKD","LU0405327494.USD","LU2097828474.EUR","LU2097828805.USD","BK0188","BK0060","600276","LU1997245094.SGD","LU1146622755.USD","LU1023057109.AUD","LU1655091616.SGD","LU2495084118.USD","LU2328871848.SGD","LU2148510915.USD","LU1328615791.USD","LU1997245177.USD","LU2097828631.EUR","LU2289578879.USD","BK0183","BK0028","BK0239","LU0359201885.HKD","LU0359202008.SGD","LU1997244956.HKD","BK0196","LU1820825898.SGD","LU2543165471.USD","LU1064130708.USD","BK0012","LU1969619763.USD","LU1580142542.USD","01276","LU2097828714.EUR","LU2097828557.USD","LU0359201612.USD","LU1255011170.USD","LU2488822045.USD","LU2580892789.USD","LU1064131003.USD","LU1781817850.SGD","BK1191","LU0405327148.USD"],"gpt_icon":1},{"id":"2593478682","title":"恒瑞医药(600276.SH)：注射用SHR-A1904纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2593478682","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593478682?lang=zh_cn&edition=full","pubTime":"2025-12-24 16:54","pubTimestamp":1766566481,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日,公司及子公司上海恒瑞医药有限公司注射用SHR-A1904被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。该药品拟定适应症(或功能主治)：既往接受至少一线系统治疗的CLDN18.2阳性的局部晚期或转移性胃或胃食管交界处腺癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","LU1781817850.SGD","LU2495084118.USD","LU2543165471.USD","BK0188","LU1997245094.SGD","BK0012","LU2148510915.USD","LU2097828805.USD","BK0028","LU1969619763.USD","LU0405327494.USD","LU1064131003.USD","LU1146622755.USD","LU0359201612.USD","LU2097828474.EUR","LU1820825898.SGD","LU0405327148.USD","LU2580892789.USD","LU1064130708.USD","LU2097828557.USD","600276","LU1997244956.HKD","LU1655091616.SGD","LU2097828714.EUR","LU2289578879.USD","LU2328871848.SGD","LU2580892862.HKD","BK0239","LU1023057109.AUD","LU0359201885.HKD","BK1191","LU2097828631.EUR","LU1328615791.USD","LU2488822045.USD","BK0196","LU0359202008.SGD","LU1580142542.USD","LU1255011170.USD","BK0060","LU1997245177.USD","BK0183"],"gpt_icon":0},{"id":"2593945147","title":"恒瑞医药祝您暖意相随，喜乐常安！","url":"https://stock-news.laohu8.com/highlight/detail?id=2593945147","media":"恒瑞医药官微","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593945147?lang=zh_cn&edition=full","pubTime":"2025-12-21 07:00","pubTimestamp":1766271600,"startTime":"0","endTime":"0","summary":"往期精选| 研发创新|| 国际化|| 重磅奖项|| 社会公益| ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251221/c673379626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0060","LU2097828714.EUR","BK0188","LU1820825898.SGD","LU1997245094.SGD","LU2097828557.USD","LU2580892862.HKD","BK0012","LU1580142542.USD","LU2097828474.EUR","BK0196","LU2097828805.USD","LU0405327148.USD","BK0239","LU1655091616.SGD","LU1328615791.USD","LU2289578879.USD","600276","LU2488822045.USD","BK0183","LU1146622755.USD","LU1255011170.USD","LU1997244956.HKD","LU1781817850.SGD","LU2097828631.EUR","LU1064130708.USD","LU2580892789.USD","LU2495084118.USD","LU2328871848.SGD","LU1997245177.USD","LU1969619763.USD","LU2148510915.USD","BK0028","LU0405327494.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2592157528","title":"恒瑞医药：SHR-9539注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2592157528","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592157528?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:11","pubTimestamp":1766135494,"startTime":"0","endTime":"0","summary":"南财智讯12月19日电，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司及子公司苏州盛迪亚生物医药有限公司、上海恒瑞医药有限公司研发的SHR-9539注射液开展临床试验。审批结论显示，同意开展SHR-9539联合治疗在多发性骨髓瘤中的IB/II期研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512193596828474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","LU1328615791.USD","LU0359201885.HKD","LU2097828631.EUR","LU1969619763.USD","LU0359201612.USD","LU2543165471.USD","LU2289578879.USD","LU1255011170.USD","LU1997245094.SGD","LU2097828474.EUR","LU1997245177.USD","600276","BK0028","LU2580892862.HKD","LU1064130708.USD","LU2580892789.USD","BK0183","LU0359202008.SGD","01276","LU1781817850.SGD","LU0405327494.USD","LU1023057109.AUD","LU2488822045.USD","LU2097828714.EUR","LU1064131003.USD","BK0188","LU2097828805.USD","BK0012","LU1997244956.HKD","LU0405327148.USD","LU1580142542.USD","LU2148510915.USD","LU1820825898.SGD","LU2328871848.SGD","BK0239","BK0060","LU2495084118.USD","LU2097828557.USD","BK1191","LU1655091616.SGD","LU1146622755.USD"],"gpt_icon":0},{"id":"2591264877","title":"小摩增持恒瑞医药(01276)387.9413万股 每股作价72.5974港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591264877","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591264877?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:59","pubTimestamp":1765796342,"startTime":"0","endTime":"0","summary":"增持后最新持股数目约为2141.30万股，最新持股比例为8.29%。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20251215/20251215185921_56798.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251215/20251215185921_56798.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0496365809.HKD","LU1997245177.USD","IE00BN8TJ469.HKD","LU1116320737.USD","LU1366192091.USD","LU0964807845.USD","LU0170899867.USD","LU0405327148.USD","LU0405327494.USD","BK4207","LU2552382215.SGD","IE00BFXG1179.USD","LU2756315664.SGD","BK4550","LU0211326755.USD","LU2417539215.USD","BK4585","BK0012","LU0359202008.SGD","LU2462157665.USD","01276","IE00BKVL7J92.USD","BK4588","LU0942090050.USD","LU2456880835.USD","BK4504","LU2495084118.USD","LU2592432038.USD","IE00BJTD4N35.SGD","LU0048584097.USD","LU2213496289.HKD","BK4566","LU2097828805.USD","600276","IE00BJLML261.HKD","LU0345769128.USD","LU0868494617.USD","LU1551013342.USD","LU1988902786.USD","LU0820561818.USD","LU1146622755.USD","LU2552382058.USD","LU1064130708.USD","LU1551013425.SGD","LU1997244956.HKD","IE00BKDWB100.SGD","LU1244550494.USD","LU0211328371.USD","LU2237443895.HKD","LU0267386448.USD"],"gpt_icon":0},{"id":"1170772367","title":"摩根大通在江苏恒瑞医药H股的多头头寸于12月9日从6.79%增至8.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170772367","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170772367?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:22","pubTimestamp":1765790560,"startTime":"0","endTime":"0","summary":"摩根大通在江苏恒瑞医药的H股多头头寸于12月9日从6.79%增加至8.29%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1781817850.SGD","LU1255011170.USD","LU1655091616.SGD","BK0239","LU1820825898.SGD","LU2488822045.USD","LU2289578879.USD","LU1969619763.USD","BK0012","LU2580892789.USD","LU2580892862.HKD","LU2495084118.USD","LU2097828805.USD","LU2148510915.USD","LU1064131003.USD","LU2097828474.EUR","LU1997245177.USD","BK0183","600276","LU1328615791.USD","LU0405327494.USD","LU0405327148.USD","LU2097828557.USD","LU2097828714.EUR","LU1064130708.USD","LU2097828631.EUR","LU1146622755.USD","BK0028","BK0188","BK0060","LU2328871848.SGD","LU1580142542.USD","LU1997245094.SGD","BK0196","LU1997244956.HKD"],"gpt_icon":0},{"id":"2591970396","title":"恒瑞医药卵巢癌治疗药物氟唑帕利FZOCUS-1研究，载入全球肿瘤学顶刊《CA》","url":"https://stock-news.laohu8.com/highlight/detail?id=2591970396","media":"新浪科技","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591970396?lang=zh_cn&edition=full","pubTime":"2025-12-15 13:59","pubTimestamp":1765778340,"startTime":"0","endTime":"0","summary":"新浪科技讯 12月15日下午消息，近日，FZOCUS-1研究登顶全球肿瘤学顶级期刊《临床医师癌症杂志》 ，这也是《CA》首次刊载由中国研究者开展的妇科肿瘤领域临床研究。在HRD阳性人群，FZOCUS-1研究证实PARP抑制剂单药运用即可实现理想疗效，避免联合用药带来的副作用与经济负担。 “FZOCUS-1研究全文在《CA》的成功发表，是中国临床肿瘤学研究的重要里程碑。”","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tech/shenji/2025-12-15/doc-inhawiaf2341954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064130708.USD","LU1997245177.USD","LU0405327148.USD","LU1255011170.USD","BK1191","BK0028","LU1781817850.SGD","LU2289578879.USD","LU2097828714.EUR","LU1997244956.HKD","LU0359201612.USD","LU0405327494.USD","01276","LU2097828474.EUR","BK0239","LU2097828805.USD","LU1023057109.AUD","BK0183","LU2543165471.USD","BK0188","600276","LU1580142542.USD","LU2328871848.SGD","LU2495084118.USD","BK0012","LU1328615791.USD","BK0060","LU0359202008.SGD","LU2580892789.USD","LU2097828557.USD","LU0359201885.HKD","CA","LU1146622755.USD","LU1655091616.SGD","LU2148510915.USD","LU2488822045.USD","LU1997245094.SGD","LU2580892862.HKD","LU1969619763.USD","BK0196","LU1064131003.USD","LU2097828631.EUR","LU1820825898.SGD"],"gpt_icon":1},{"id":"2591699288","title":"国信证券：FXI抑制剂有望成为下一代抗凝药物 建议关注恒瑞医药(600276.SH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2591699288","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591699288?lang=zh_cn&edition=full","pubTime":"2025-12-15 10:41","pubTimestamp":1765766465,"startTime":"0","endTime":"0","summary":"建议关注恒瑞医药：FXI单抗SHR-2004进入3期临床，在国产分子中领先;并关注拥有FXI小核酸药物管线的公司。国信证券主要观点如下：FXI/FXIa抑制剂有望成为安全性更优的抗凝药物现有抗凝血药物均作用于凝血的共同通路，FXI仅参与内源性凝血通路以及血栓的正反馈放大，抑制FXI活性有望在抗凝血的同时减少出血的风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828714.EUR","LU0405327148.USD","LU2488822045.USD","LU1997245177.USD","600276","002736","LU2148510915.USD","BK0188","LU1328615791.USD","BK0012","LU1255011170.USD","BK0239","BK0028","LU1997245094.SGD","LU2097828631.EUR","LU2580892862.HKD","BK0183","LU2097828474.EUR","BK0276","LU0359201612.USD","LU0359201885.HKD","LU0359202008.SGD","LU1023057109.AUD","LU2328871848.SGD","01276","LU0405327494.USD","LU1997244956.HKD","BK0196","LU1820825898.SGD","LU2097828557.USD","LU1146622755.USD","LU2289578879.USD","LU2543165471.USD","LU1969619763.USD","LU1580142542.USD","BK1191","LU2580892789.USD","LU1781817850.SGD","BK0060","LU1064131003.USD","LU1064130708.USD","LU1655091616.SGD","LU2097828805.USD","LU2495084118.USD"],"gpt_icon":0},{"id":"2590577652","title":"12月12日恒瑞医药现1笔大宗交易 机构净卖出358.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590577652","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590577652?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:57","pubTimestamp":1765533451,"startTime":"0","endTime":"0","summary":"证券之星消息，12月12日恒瑞医药发生大宗交易，交易数据如下：大宗交易成交价格63.28元，成交5.66万股，成交金额358.16万元，买方营业部为国泰海通证券股份有限公司总部，卖方营业部为机构专用。近三个月该股共发生3笔大宗交易，合计成交1.12万手。截至2025年12月12日收盘，恒瑞医药报收于63.28元，下跌0.19%，换手率0.49%，成交量31.56万手，成交额19.85亿元。该股最近90天内共有22家机构给出评级，买入评级21家，增持评级1家；过去90天内机构目标均价为83.75。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200029064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","LU2097828714.EUR","BK0188","LU1820825898.SGD","LU1997245094.SGD","LU2097828557.USD","LU2580892862.HKD","BK0012","LU1580142542.USD","LU2097828474.EUR","BK0196","LU2097828805.USD","LU0359201612.USD","LU1023057109.AUD","01276","LU0405327148.USD","LU0359201885.HKD","BK0239","LU1655091616.SGD","LU1328615791.USD","LU2289578879.USD","600276","BK1191","LU2488822045.USD","BK0183","LU1146622755.USD","LU1255011170.USD","LU1997244956.HKD","LU1781817850.SGD","LU2097828631.EUR","LU1064130708.USD","LU2580892789.USD","LU0359202008.SGD","LU2543165471.USD","LU2495084118.USD","LU2328871848.SGD","LU1997245177.USD","LU1969619763.USD","LU2148510915.USD","BK0028","LU0405327494.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2590574915","title":"恒瑞医药：SHR-A1811(sc)注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590574915","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590574915?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:06","pubTimestamp":1765530411,"startTime":"0","endTime":"0","summary":"南财智讯12月12日电，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的关于SHR-A1811(sc)注射液的《药物临床试验批准通知书》，同意该药品单药在晚期实体瘤患者中开展临床试验。SHR-A1811(sc)注射液为公司开发的皮下制剂，是在已获批上市的注射用瑞康曲妥珠单抗（SHR-A1811）基础上优化而来，旨在缩短给药时间、提升便捷性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512123590226438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","600276","LU2097828805.USD","LU2543165471.USD","LU1580142542.USD","LU2097828714.EUR","LU1997245177.USD","LU2488822045.USD","BK0028","LU0405327148.USD","LU2580892862.HKD","LU1655091616.SGD","LU2148510915.USD","BK0060","LU1820825898.SGD","LU0359201612.USD","LU0359201885.HKD","LU2580892789.USD","BK0196","LU1969619763.USD","01276","BK0239","LU1064131003.USD","LU1146622755.USD","LU2495084118.USD","LU1997245094.SGD","LU1997244956.HKD","LU2097828631.EUR","LU1023057109.AUD","LU2097828474.EUR","LU0405327494.USD","LU2328871848.SGD","BK0183","BK0012","LU1064130708.USD","LU2097828557.USD","LU1781817850.SGD","LU2289578879.USD","LU0359202008.SGD","LU1255011170.USD","LU1328615791.USD","BK1191"],"gpt_icon":0},{"id":"2590359451","title":"恒瑞医药（600276）披露召开2025年第二次临时股东会通知，12月11日股价上涨0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590359451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590359451?lang=zh_cn&edition=full","pubTime":"2025-12-11 17:56","pubTimestamp":1765446968,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，恒瑞医药报收于63.4元，较前一交易日上涨0.03%，最新总市值为4207.98亿元。近日，恒瑞医药发布关于召开2025年第二次临时股东会的通知。公告显示，江苏恒瑞医药股份有限公司将于2025年12月31日召开2025年第二次临时股东会，会议采取现场与网络投票相结合方式，网络投票通过上海证券交易所系统进行。股权登记日为2025年12月22日，A股股东可参会。股东可于2025年12月23日办理登记。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100029366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2097828714.EUR","LU1969619763.USD","LU2148510915.USD","LU0359201612.USD","LU0359202008.SGD","LU1064131003.USD","LU1255011170.USD","600276","LU2097828631.EUR","LU1997245094.SGD","01276","LU1064130708.USD","LU2097828557.USD","LU1580142542.USD","BK1191","LU2289578879.USD","LU2495084118.USD","LU1997245177.USD","BK0183","LU1655091616.SGD","LU0405327148.USD","LU2580892789.USD","LU2543165471.USD","LU0359201885.HKD","BK0028","LU2097828474.EUR","LU2488822045.USD","BK0196","LU1781817850.SGD","LU1328615791.USD","BK0012","LU1820825898.SGD","BK0188","LU2097828805.USD","BK0060","LU2580892862.HKD","LU1997244956.HKD","LU2328871848.SGD","LU0405327494.USD","LU1146622755.USD","BK0239","LU1023057109.AUD"],"gpt_icon":0},{"id":"2589748728","title":"恒瑞医药(01276)药品纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589748728","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589748728?lang=zh_cn&edition=full","pubTime":"2025-12-07 18:42","pubTimestamp":1765104127,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，根据国家医保局、人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生育保险药品目录》的通知，江苏恒瑞医药股份有限公司部分产品纳入国家医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","LU0359201612.USD","LU1997244956.HKD","LU2495084118.USD","LU1328615791.USD","LU1146622755.USD","LU1255011170.USD","LU2148510915.USD","BK0239","LU2097828474.EUR","LU1655091616.SGD","LU0405327494.USD","LU1997245094.SGD","LU1580142542.USD","BK0196","LU2097828631.EUR","LU1781817850.SGD","LU1064130708.USD","LU2097828714.EUR","BK0188","LU1820825898.SGD","LU2097828557.USD","LU2289578879.USD","LU2097828805.USD","LU0359202008.SGD","BK1191","600276","LU2580892862.HKD","LU2488822045.USD","BK0012","LU0359201885.HKD","LU2580892789.USD","BK0060","BK0183","LU0405327148.USD","LU2543165471.USD","LU1023057109.AUD","LU2328871848.SGD","BK0028","LU1997245177.USD","01276","LU1969619763.USD"],"gpt_icon":1},{"id":"2589879683","title":"恒瑞医药最新公告：9款药品首次纳入国家医保目录11款药品新增或续约成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2589879683","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589879683?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:20","pubTimestamp":1765095636,"startTime":"0","endTime":"0","summary":"恒瑞医药(600276.SH)公告称，公司9款药品首次纳入国家医保目录，包括注射用瑞康曲妥珠单抗、苹果酸法米替尼胶囊等。同时，11款药品新增适应症或续约成功，包括注射用卡瑞利珠单抗、氟唑帕利胶囊等。这些药品2024年度合计销售额约为86.60亿元，2025年1-3季度合计销售额约为75.54亿元。国家医保目录（2025年）将于2026年1月1日起正式实施。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700003972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2097828714.EUR","LU0405327148.USD","LU2488822045.USD","LU1997245177.USD","600276","LU2148510915.USD","BK0188","LU1328615791.USD","BK0012","LU1255011170.USD","BK0239","BK0028","LU1997245094.SGD","LU2097828631.EUR","LU2580892862.HKD","BK0183","LU2097828474.EUR","LU0359201612.USD","LU0359201885.HKD","LU0359202008.SGD","LU1023057109.AUD","LU2328871848.SGD","01276","LU0405327494.USD","LU1997244956.HKD","BK0196","LU1820825898.SGD","LU2097828557.USD","LU1146622755.USD","LU2289578879.USD","LU2543165471.USD","LU1969619763.USD","LU1580142542.USD","BK1191","LU2580892789.USD","LU1781817850.SGD","BK0060","LU1064131003.USD","LU1064130708.USD","LU1655091616.SGD","LU2097828805.USD","LU2495084118.USD"],"gpt_icon":0},{"id":"2589815220","title":"最新富时罗素中国调仓全解读","url":"https://stock-news.laohu8.com/highlight/detail?id=2589815220","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589815220?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:15","pubTimestamp":1764836100,"startTime":"0","endTime":"0","summary":"12月3日，富时罗素2025年最后一轮中国指数季度审核结果正式揭晓，富时罗素中国指数的动态之所以受到关注，是因为该指数是全球众多金融产品的基准指标，被国内外投资者视为衡量中国股市表现的领先指标之一，其成分股的调整通常会牵动数以千亿计被动资金的走向，据富时罗素数据，在全球发行的中国主题交易所交易基金中，有近六成的资产管理规模追踪富时中国指数。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650512029&idx=1&sn=d419731b1974f74ceb6db737f419d7c7&chksm=f260eff2c51766e4228d8854d16cd230e3742b4a2f6bd40ab93181c21d49095c18903cb90d83#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU1051769294.HKD","LU0117841782.USD","LU0577902298.EUR","LU0572940350.SGD","BK1588","600276","LU1044874839.SGD","600919","LU0052750758.USD","LU0348814723.USD","LU1105468828.SGD","LU1152091754.HKD","LU1366334651.USD","BK1589","HEXmain","LU1224709979.USD","LU0831103253.SGD","SG9999001093.SGD","LU0261947096.USD","HKXCY","LU1130305938.SGD","LU0348816934.USD","LU1251922891.USD","BK1592","LU0359202008.SGD","LU0572944931.SGD","LU0594300179.USD","LU1303224171.USD","LU0630378429.USD","LU0918141705.HKD","LU2226246903.HKD","LU2213484517.USD","LU0791590937.USD","LU2543165471.USD","BK1191","06066","LU1770034418.SGD","82333","LU0797268264.HKD","BK1119","LU1166156734.SGD","LU0955669360.SGD","LU1720050803.USD","LU1242518857.USD","LU0702159699.USD","LU0762540952.USD","LU1064131003.USD","300750","LU0320764599.SGD","LU0516423091.SGD","LU0856984785.SGD","LU0067412154.USD","LU1048596156.SGD","LU1226287529.USD","BK1500","513600","LU0264606111.USD","LU1807302812.USD","SG9999002463.SGD","SG9999001051.SGD","LU0417516902.SGD","LU0821914370.USD","02833","LU1152091168.USD","SG9999002562.SGD","BK1175","GWLLY","LU0043850808.USD","LU0762542818.HKD","LU0469268626.HKD","IE0003851619.USD","LU0048580855.USD","LU1211504680.USD","LU1282649810.SGD","IE00BKZH1Z71.USD","LU0169518387.USD","300274","LU0516423174.USD","LU2039709279.SGD","002352","LU1023057109.AUD","LU1831875114.USD","LU1282649141.HKD","LU0831093199.SGD","LU0197773160.USD","LU0501845795.SGD","LU1242518931.SGD","601066","LU2257852520.SGD","LU1048588211.SGD","06936","IE00BZ08YS42.EUR","BK1116","603993","LU0084288322.USD","LU0880133367.SGD","LU0165289439.USD","LU0594300419.USD","LU1880383440.USD","LU0096374516.USD","LU1051768304.USD","LU1515016050.SGD","BK1587","LU0072462343.USD","LU0197773673.USD","LU1044876610.USD","SGXZ90724238.SGD","SG9999004220.SGD","LU0370786039.SGD","LU0572939691.SGD","BK1564","LU0164880469.USD","BK1539","LU0516422366.SGD","LU0072913022.USD","LU0348827113.USD","LU0577902371.SGD","BK1190","LU0634319403.HKD","LU0873338254.USD","LU0516422440.USD","LU0955623706.USD","LU1044875133.USD","LU0516422952.EUR","BK1594","LU0648948544.HKD","LU0819123356.HKD","LU2148510915.USD","LU0588546209.SGD","601633","LU0651946864.USD","LU1504937902.USD","MCHmain","LU1719994722.HKD","LU0540923850.HKD","LU0106959298.USD","LU0314109678.HKD","LU0348825331.USD","LU0762541174.USD","LU0593848301.USD","LU0307460666.USD","LU1282649067.USD","LU1366334578.USD","BK1610","LU0348735423.USD","LU0417516738.SGD","LU1880383366.USD","LU0149721374.USD","LU2449936058.SGD","LU0737861699.HKD","IE00B3T34201.USD","LU0327786744.USD","IE0003795394.USD","LU1813983027.USD","LU0577902538.SGD","LU1993786604.SGD","LU0173614495.USD","LU0287142896.SGD","LU0196878994.USD","BK1575","LU0577902611.USD","LU0979878070.USD","01378","LU1064130708.USD","LU0886674414.USD","LU0149534421.HKD","IE00BZ08YT58.USD","LU0918141887.USD","HHImain","LU0708995583.HKD","LU1282648689.USD","LU1642822792.SGD","LU0140636845.USD","SG9999001846.SGD","LU0211977185.USD","LU0605514214.HKD","LU0898667661.SGD","LU1481107354.HKD","LU1328277881.USD","LU0607220059.USD","LU0630378692.HKD","LU1960683339.HKD","LU1734074674.USD","LU0456846285.SGD","LU1794554557.SGD","LU0359201612.USD","BK1521","LU0359201885.HKD","LU0791591158.USD","01276","BK1147","IE00BZ08YR35.GBP","BK1151","LU0061477393.USD","80388","LU0577902454.USD","LU0651947912.USD","02333","LU0488056044.USD","LU1981816686.USD","LU0650527681.SGD","LU1008478684.HKD","MHImain","BK1131","LU0819121731.USD","03993","LU0251144936.SGD","LU0561508036.HKD","LU0955648018.USD","LU0384037296.USD","LU0048597586.USD"],"gpt_icon":1},{"id":"2588109870","title":"富时中国50指数调整：纳入中国宏桥(01378)、宁德时代(03750)、恒瑞医药(01276)，剔除中信建投证券(06066)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2588109870","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588109870?lang=zh_cn&edition=full","pubTime":"2025-12-03 18:40","pubTimestamp":1764758405,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月3日，富时罗素宣布对富时中国50指数、富时中国A50指数、富时中国A150指数、富时中国A200指数及富时中国A400指数进行审议调整，该调整将于2025年12月19日(星期五)收盘后生效。其中，本次富时中国50指数成分股将纳入中国宏桥、宁德时代、恒瑞医药等港股，将剔除中信建投证券H股、长城汽车H股、理想汽车-W等港股公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377153.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","LU0821914370.USD","LU2348774022.SGD","LU0011963245.USD","LU0611395673.USD","JKS","LU1934453819.USD","LU0702159699.USD","LU2506951792.HKD","LU0880133367.SGD","LU1152091168.USD","01276","LU1861214812.USD","LU2495084118.USD","IE00B8L5B284.USD","LU1166156734.SGD","LU0651947912.USD","LU0326950275.SGD","BK4526","BK1500","LU2506952410.USD","LU2580892789.USD","LU1794554557.SGD","LU0359201612.USD","LU0072462343.USD","LU0231483743.USD","BK0239","LU1720050803.USD","LU0463099449.HKD","LU0516422440.USD","EVS.SI","LU0107464264.USD","LU1781817850.SGD","LU1861219969.SGD","LU0106252389.USD","LU0594300179.USD","LU1224709979.USD","LU1979443071.USD","600276","LU0039217434.USD","03750","06066","LU0531971595.HKD","LU0302445910.USD","01378","LU0140636845.USD","LU1719994722.HKD","LU0328353924.USD","300750","LU0651946864.USD"],"gpt_icon":0},{"id":"2588014759","title":"恒瑞医药最新公告：董事会提名聘任朱国新为公司高级副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2588014759","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588014759?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:34","pubTimestamp":1764754490,"startTime":"0","endTime":"0","summary":"恒瑞医药公告称，公司第九届董事会第二十次会议于2025年12月3日召开，会议审议并通过了《关于提名聘任公司高级副总裁的议案》，提名聘任朱国新为公司高级副总裁，任期自本次董事会审议通过之日起至本届董事会任期届满为止。朱国新拥有30余年全球跨职能药物发现领导经验，涉及多个疾病领域。加入恒瑞医药前，他在礼来新药研发中心担任副总裁，领导了多个发现研究和早期开发项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300027544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1997245177.USD","LU2148510915.USD","LU0405327148.USD","LU0405327494.USD","BK0239","LU1580142542.USD","BK0188","LU2488822045.USD","LU1969619763.USD","BK0012","BK0028","LU2097828631.EUR","LU1023057109.AUD","BK0183","LU0359202008.SGD","LU2097828557.USD","01276","BK1191","LU1328615791.USD","LU2097828714.EUR","LU2495084118.USD","LU1820825898.SGD","LU1781817850.SGD","LU1255011170.USD","LU1655091616.SGD","LU2097828805.USD","600276","LU2328871848.SGD","BK0196","BK0060","LU1146622755.USD","LU1064130708.USD","LU1997244956.HKD","LU0359201885.HKD","LU2289578879.USD","LU2543165471.USD","LU2580892862.HKD","LU2580892789.USD","LU1064131003.USD","LU2097828474.EUR","LU0359201612.USD","LU1997245094.SGD"],"gpt_icon":0},{"id":"2588398720","title":"恒瑞医药回购890万股 金额5.95亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588398720","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588398720?lang=zh_cn&edition=full","pubTime":"2025-12-02 17:37","pubTimestamp":1764668274,"startTime":"0","endTime":"0","summary":"12月2日，恒瑞医药（600276/01276）发布公告，截至2025年11月30日已回购890万股，占总股本的0.13%，回购资金总额为5.95亿元，回购价格区间为59.32元/股至70元/股。2025年前三季度，恒瑞医药实现收入231.88亿元，归母净利润57.51亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512023580451214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600276","LU0405327148.USD","LU1023057109.AUD","LU2580892789.USD","LU1997245177.USD","LU2097828474.EUR","LU1146622755.USD","LU1997245094.SGD","LU0359201885.HKD","LU2495084118.USD","BK0196","LU2097828631.EUR","LU2289578879.USD","LU1064131003.USD","LU1580142542.USD","LU2148510915.USD","BK0060","BK0012","LU1781817850.SGD","LU1997244956.HKD","LU2488822045.USD","BK1191","LU1969619763.USD","LU2097828714.EUR","LU2097828557.USD","LU2580892862.HKD","BK0239","LU2097828805.USD","LU1655091616.SGD","LU1255011170.USD","LU1328615791.USD","BK0028","BK0183","LU2543165471.USD","01276","LU0359202008.SGD","BK0188","LU0359201612.USD","LU2328871848.SGD","LU1064130708.USD","LU0405327494.USD","LU1820825898.SGD"],"gpt_icon":0},{"id":"2588727841","title":"GIC Private Limited增持恒瑞医药(01276)42.24万股 每股作价约74.96港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727841","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588727841?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:27","pubTimestamp":1764592054,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，11月27日，GIC Private Limited增持恒瑞医药(01276)42.24万股，每股作价74.955港元，总金额约为3166.1万港元。增持后最新持股数目为5946.22万股，最新持股比例为23.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376177.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1146622755.USD","LU1820825898.SGD","LU0405327494.USD","BK0060","BK0188","LU2097828474.EUR","LU2543165471.USD","BK4104","GIC","LU1255011170.USD","LU1064131003.USD","LU2289578879.USD","BK0196","LU1781817850.SGD","LU0359201885.HKD","LU2097828714.EUR","LU0359202008.SGD","01276","LU2328871848.SGD","LU0405327148.USD","LU2580892862.HKD","LU2097828805.USD","BK0183","LU0359201612.USD","LU2495084118.USD","LU1969619763.USD","BK0028","LU2097828631.EUR","BK0239","BK0012","LU1023057109.AUD","BK1191","LU2097828557.USD","LU1997245177.USD","LU1064130708.USD","LU1997244956.HKD","LU1997245094.SGD","LU1580142542.USD","LU1655091616.SGD","LU2148510915.USD","600276","LU2488822045.USD","LU1328615791.USD","LU2580892789.USD"],"gpt_icon":0},{"id":"2586127392","title":"恒瑞医药获大摩增持约177.06万股 每股均价69.65港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586127392","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586127392?lang=zh_cn&edition=full","pubTime":"2025-11-28 07:27","pubTimestamp":1764286020,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 香港联交所最新资料显示，11月24日，大摩增持恒瑞医药（01276）177.0645万股，每股均价69.65港元，总金额约为1.23亿港元。增持后最新持股数目约为2084.8万股，最新持股比例为8.07%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-11-28/doc-infywyzq8672404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1328615791.USD","BK4516","IE00BZ1G4Q59.USD","LU0234570918.USD","LU1655091616.SGD","LU2097828714.EUR","LU1997245094.SGD","LU1023057109.AUD","LU2148510915.USD","BK0196","LU0225283273.USD","LU2580892862.HKD","LU1668664300.SGD","LU1064130708.USD","LU2289578879.USD","LU0158827781.USD","LU2097828557.USD","LU0314104364.USD","LU1732800096.USD","LU1791710582.SGD","LU2028103732.USD","BK4588","BK0188","LU0359201885.HKD","LU1074936037.SGD","LU0006306889.USD","LU2133065610.SGD","LU0405327148.USD","LU1244550221.USD","LU2580892789.USD","BK1191","BK0183","01276","LU0528227936.USD","LU1244550494.USD","LU2328871848.SGD","BK0028","600276","LU1969619763.USD","LU2357305700.SGD","LU1720051017.SGD","LU2543165471.USD","BK4534","LU1720051108.HKD","BK0012","LU1255011170.USD","LU1820825898.SGD","LU0359202008.SGD","LU1162221912.USD","LU0359201612.USD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766665383381,"stockEarnings":[{"period":"1week","weight":0.0154},{"period":"1month","weight":0.0094},{"period":"3month","weight":-0.1528},{"period":"6month","weight":0.1786},{"period":"1year","weight":0.3264},{"period":"ytd","weight":0.3388}],"compareEarnings":[{"period":"1week","weight":0.0183},{"period":"1month","weight":0.0272},{"period":"3month","weight":0.0227},{"period":"6month","weight":0.1509},{"period":"1year","weight":0.1613},{"period":"ytd","weight":0.1758}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"397246人(较上一季度增加8.94%)","perCapita":"16058股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇胺片、碘佛醇注射液。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}